Amgen Presented New Lumakras (Sotorasib) Plus Chemotherapy Data In First-line Kras G12c NASLC At WCLC; Said Data Demonstrated A Confirmed Objective Response Rate Of 65%
Portfolio Pulse from Charles Gross
Amgen has announced promising data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating Lumakras with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer. The data showed a confirmed objective response rate of 65% in patients treated in the first-line setting.
September 10, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's Lumakras has shown promising results in a Phase 1b study for advanced non-small cell lung cancer, which could potentially boost the company's stock in the short term.
The promising results from the Phase 1b study of Lumakras, a drug developed by Amgen, could potentially lead to increased investor confidence in the company. This could result in a short-term increase in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100